Abstract
We show correlation between strong and decreased NY-ESO-1-specific immunity with spontaneous regression and subsequent recurrence, respectively, in a long-surviving patient with an NY-ESO-1-expressing lung adenocarcinoma. An integrated immune response consisting of IgG antibody, as well as CD4 and CD8 T cells, against NY-ESO-1 was observed at the time of spontaneous regression of multiple pleural metastases. After tumor dormancy for 3 years, the tumor started to progress. IgG antibody levels and the number of CD4 and CD8 T cells against NY-ESO-1 decreased, but were still detectable. On the other hand, the number of Foxp3+ CD25 high T regulatory cells gradually increased. The findings suggest the relevance of the NY-ESO-1 immune response and its regulation by Foxp3+ CD25 high T regulatory cells in the clinical course of this lung cancer patient.
| Original language | English |
|---|---|
| Pages (from-to) | 8 |
| Number of pages | 1 |
| Journal | Cancer immunity : a journal of the Academy of Cancer Immunology |
| Volume | 9 |
| Publication status | Published - Jan 19 2009 |
Fingerprint
Keywords
- Cellular immunity
- Human
- Humoral immunity
- Lung cancer
- NY-ESO-1
ASJC Scopus subject areas
- Cancer Research
- Immunology
Cite this
Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient. / Isobe, Midori; Eikawa, Shingo; Uenaka, Akiko; Nakamura, Yoichi; Kanda, Tetsuo; Kohno, Shigeru; Kuzushima, Kiyotaka; Nakayama, Eiichi.
In: Cancer immunity : a journal of the Academy of Cancer Immunology, Vol. 9, 19.01.2009, p. 8.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient
AU - Isobe, Midori
AU - Eikawa, Shingo
AU - Uenaka, Akiko
AU - Nakamura, Yoichi
AU - Kanda, Tetsuo
AU - Kohno, Shigeru
AU - Kuzushima, Kiyotaka
AU - Nakayama, Eiichi
PY - 2009/1/19
Y1 - 2009/1/19
N2 - We show correlation between strong and decreased NY-ESO-1-specific immunity with spontaneous regression and subsequent recurrence, respectively, in a long-surviving patient with an NY-ESO-1-expressing lung adenocarcinoma. An integrated immune response consisting of IgG antibody, as well as CD4 and CD8 T cells, against NY-ESO-1 was observed at the time of spontaneous regression of multiple pleural metastases. After tumor dormancy for 3 years, the tumor started to progress. IgG antibody levels and the number of CD4 and CD8 T cells against NY-ESO-1 decreased, but were still detectable. On the other hand, the number of Foxp3+ CD25 high T regulatory cells gradually increased. The findings suggest the relevance of the NY-ESO-1 immune response and its regulation by Foxp3+ CD25 high T regulatory cells in the clinical course of this lung cancer patient.
AB - We show correlation between strong and decreased NY-ESO-1-specific immunity with spontaneous regression and subsequent recurrence, respectively, in a long-surviving patient with an NY-ESO-1-expressing lung adenocarcinoma. An integrated immune response consisting of IgG antibody, as well as CD4 and CD8 T cells, against NY-ESO-1 was observed at the time of spontaneous regression of multiple pleural metastases. After tumor dormancy for 3 years, the tumor started to progress. IgG antibody levels and the number of CD4 and CD8 T cells against NY-ESO-1 decreased, but were still detectable. On the other hand, the number of Foxp3+ CD25 high T regulatory cells gradually increased. The findings suggest the relevance of the NY-ESO-1 immune response and its regulation by Foxp3+ CD25 high T regulatory cells in the clinical course of this lung cancer patient.
KW - Cellular immunity
KW - Human
KW - Humoral immunity
KW - Lung cancer
KW - NY-ESO-1
UR - http://www.scopus.com/inward/record.url?scp=73449144847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73449144847&partnerID=8YFLogxK
M3 - Article
C2 - 19791734
AN - SCOPUS:74749106888
VL - 9
SP - 8
JO - Cancer immunology research
JF - Cancer immunology research
SN - 2326-6066
ER -